文献速递免疫规划卫生政策与健康促进

重新评估112个低收入和中等收入国家5岁以下儿童引入肺炎球菌结合疫苗的影响与成本效果:一项模型研究

Re-evaluating the impact and cost-effectiveness of pneumococcal conjugate vaccine introduction in 112 low-income and middle-income countries in children younger than 5 years: a modelling study.
PubMed 文献 · Lancet Glob Health · 2024-01-01

该模型研究更新了伪动力学模型,估计在112个低收入和中等收入国家5岁以下儿童中引入13价肺炎球菌结合疫苗(PCV13)的影响与成本效果。结果显示,使用各国实际疫苗覆盖率,2000-2030年间PCV13可预防697 000例死亡、46.0百万伤残调整生命年(DALY)和131百万病例;每避免一个DALY的增量成本为国际元851。若2020年PCV覆盖率提升至百白破疫苗水平,可额外预防146 000例死亡。

要点

  • 2000-2030年间,PCV13在112国可预防697 000例5岁以下儿童死亡。
  • PCV13可预防46.0百万DALY和131百万病例。
  • 每避免一个DALY的增量成本为国际元851。

核心结论

  • 将来自低收入环境的真实世界证据纳入模型后显示,全球PCV推广延迟和PCV覆盖率低已导致大量生命损失。
  • 疫苗引入延迟或疫苗覆盖率低的国家经历了许多本可通过PCV预防的死亡。
  • 这些发现强调需要快速扩大PCV接种以达到高覆盖率并最大化疫苗影响。

研究设计与样本

  • 更新现有伪动力学模型,纳入各国疫苗覆盖率、疾病负担和引入后疫苗影响的新证据,估计PCV13在112个低收入和中等收入国家的影响。
  • 估计2000-2030年出生的5岁以下儿童的死亡、DALY和避免病例数,使用各国特定PCV覆盖率及覆盖率提升至百白破(DTP)水平的假设情景。
  • 进行了概率不确定性分析。

主要发现

  • 使用各国特定疫苗覆盖率,估计2000-2030年间PCV13在112国可预防697 000例死亡(95%可信区间359 000-1 040 000)。
  • PCV13可预防46.0百万DALY(95%可信区间24.0-68.9)和131百万病例(95%可信区间89.0-172)。
  • PCV估计可预防2000-2030年间5岁以下儿童肺炎球菌死亡的5.3%。
  • 疫苗接种的增量成本为每避免一个DALY国际元851(95%可信区间510-1530)。
  • 若2020年PCV覆盖率提升至DTP覆盖率,PCV13可额外预防146 000例死亡(95%可信区间75 500-219 000)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Streptococcus pneumoniae has been estimated to cause 9·18 million cases of pneumococcal pneumonia, meningitis, and invasive non-pneumonia non-meningitis disease and 318 000 deaths among children younger than 5 years in 2015. We estimated the potential impact and cost-effectiveness of pneumococcal conjugate vaccine (PCV) introduction. METHODS: We updated our existing pseudodynamic model to estimate the impact of 13-valent PCV (PCV13) in 112 low-income and middle-income countries by adapting our previously published pseudodynamic model with new country-specific evidence on vaccine coverage, burden, and post-introduction vaccine impact from WHO-UNICEF estimates of national immunisation coverage and a global burden study. Deaths, disability-adjusted life-years (DALYs), and cases averted were estimated for children younger than 5 years born between 2000 and 2030. We used specific PCV coverage in each country and a hypothetical scenario in which coverage increased to diphtheria-tetanus-pertussis (DTP) levels. We conducted probabilistic uncertainty analyses. FINDINGS: Using specific vaccine coverage in countries, we estimated that PCV13 could prevent 697 000 (95% credibility interval 359 000-1 040 000) deaths, 46·0 (24·0-68·9) million DALYs, and 131 (89·0-172) million cases in 112 countries between 2000 and 2030. PCV was estimated to prevent 5·3% of pneumococcal deaths in children younger than 5 years during 2000-30. The incremental cost of vaccination would be I$851 (510-1530) per DALY averted. If PCV coverage were increased to DTP coverage in 2020, PCV13 could prevent an additional 146 000 (75 500-219 000) deaths. INTERPRETATION: The inclusion of real-world evidence from lower-income settings revealed that delays in PCV roll-out globally and low PCV coverage have cost many lives. Countries with delays in vaccine introduction or low vaccine coverage have experienced many PCV-preventable deaths. These findings underscore the importance of rapidly scaling up PCV to achieve high coverage and maximise vaccine impact. FUNDING: Bill & Melinda Gates Foundation and Gavi, the Vaccine Alliance.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Chen C, Ang G, Akksilp K, et al. Re-evaluating the impact and cost-effectiveness of pneumococcal conjugate vaccine introduction in 112 low-income and middle-income countries in children younger than 5 years: a modelling study. Lancet Glob Health. 2024. PMID: 39151983. doi:10.1016/S2214-109X(24)00232-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。